Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
37.51
-0.29 (-0.77%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Surmodics Revenue
Surmodics had revenue of $30.34M in the quarter ending June 30, 2024, a decrease of -42.19%. This brings the company's revenue in the last twelve months to $120.82M, down -7.49% year-over-year. In the fiscal year ending September 30, 2023, Surmodics had annual revenue of $132.58M with 32.65% growth.
Revenue (ttm)
$120.82M
Revenue Growth
-7.49%
P/S Ratio
4.38
Revenue / Employee
$321,332
Employees
376
Market Cap
535.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2023 | 132.58M | 32.63M | 32.65% |
| Sep 30, 2022 | 99.95M | -5.19M | -4.93% |
| Sep 30, 2021 | 105.14M | 10.27M | 10.83% |
| Sep 30, 2020 | 94.86M | -5.21M | -5.21% |
| Sep 30, 2019 | 100.08M | 18.74M | 23.04% |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
| Sep 30, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Community Health Systems | 12.55B |
| Varex Imaging | 832.70M |
| Arcturus Therapeutics Holdings | 163.87M |
| Cartesian Therapeutics | 54.10M |
| Prime Medicine | 591.00K |
| Allogene Therapeutics | 65.00K |
SRDX News
- 4 weeks ago - Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter - Business Wire
- 3 months ago - Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results - Business Wire
- 3 months ago - SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX - Business Wire
- 5 months ago - Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. - Business Wire
- 5 months ago - SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX - Accesswire
- 5 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc. - PRNewsWire
- 5 months ago - Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million - Business Wire
- 6 months ago - Surmodics, Inc. (SRDX) Q2 2024 Earnings Call Transcript - Seeking Alpha